Management Change/Compensation (Form 8-K)

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On April 6, 2026, Bruker Corporation (the "Company") and Falko Busse, Ph.D., an executive officer of the Company and President of the Bruker BioSpin Group ("Bruker BioSpin"), a wholly owned subsidiary of the Company, agreed that his duties as executive officer with the Company and as President of Bruker BioSpin would transition on or around May 1, 2026 and that his employment with the Company and Bruker BioSpin would terminate as of October 31, 2026 (the "Separation Date").

In connection with Dr. Busse's departure, Bruker Switzerland AG and Dr. Busse entered into a mutual separation agreement (the "Separation Agreement"), dated as of April 7, 2026. The Separation Agreement provides for separation benefits including severance, pro-rated bonus, and a payout for unused vacation days in an aggregate amount of CHF equal to approximately $1,020,351 to be paid upon the Separation Date. In addition, consistent with the provisions of the applicable plans and award agreements, Dr. Busse shall forfeit any unvested equity awards that he may hold on the Separation Date.

The Separation Agreement also contains customary provisions, including restrictive covenants and confidentiality, non-solicitation, and non-disparagement obligations.

The foregoing summary of the Separation Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Separation Agreement, a copy of which will be filed as an exhibit to the Company's Quarterly Report on Form 10-Q for the fiscal quarter ending June 30, 2026.